CDA | Evidence Driven
CDA | Evidence Driven

Glatiramer acetate

Details

Files
Generic Name:
Glatiramer acetate
Project Status:
Complete
Therapeutic Area:
Relapsing Remitting Multiple Sclerosis (RRMS)
Manufacturer:
Pendopharm
Call for patient/clinician input open:
Brand Name:
Glatect
Project Line:
Reimbursement Review
Project Number:
SE0510-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Submission Type:
Initial
Indications:
Multiple Sclerosis, relapsing - remitting
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:

Files

Submission Status Report View PDF
Recommendation and Reasons View PDF
Patient Group Input Submissions View PDF
Subsequent Entry Non-Biologic Complex Drug Submission View PDF
Last Updated : December 15, 2016